REGULATION OF EXPERIMENTAL THERAPY REIMBURSEMENT

1. INTRODUCTION

Experimental therapy reimbursement concerns the payment or repayment of expenses incurred for treatments that remain investigational, lack full regulatory approval, or are administered through clinical trials or exceptional access arrangements. It raises important questions about patient safety, healthcare financing, insurance coverage, medical necessity, and the legal responsibility of sponsors and public authorities.

The legal position depends on whether the expense arises from participation in a clinical trial, treatment-related injury, compassionate access to an investigational medicine, or a patient's independent decision to obtain experimental treatment. These situations are legally distinct. Reimbursement is not automatically available merely because a treatment is experimental or expensive.

2. LEGAL FRAMEWORK IN INDIA

A. NEW DRUGS AND CLINICAL TRIALS RULES, 2019

Rules 39–43 establish provisions concerning medical management and compensation for qualifying clinical-trial-related injuries and deaths. Rule 40 requires sponsors to provide free medical management for trial-related injury for the prescribed period. Rule 39 provides for financial compensation in qualifying cases, in addition to medical-management expenses. Rule 41 identifies circumstances in which injury or death is considered related to a clinical trial.

These provisions do not establish a universal right to reimbursement for every experimental therapy obtained outside a regulated trial. Their application depends on the relevant research activity and statutory conditions.

B. CONSTITUTIONAL RIGHT TO HEALTH

Article 21 of the Constitution protects life and personal liberty. Judicial decisions have recognised the importance of access to healthcare, particularly where State authorities administer public medical facilities or reimbursement schemes.

However, the constitutional right to health does not automatically require the government to finance every unapproved or investigational treatment. Eligibility, medical necessity, applicable policy, and the legality of the treatment remain relevant.

C. HEALTH INSURANCE AND PUBLIC REIMBURSEMENT

Insurance reimbursement depends on the applicable policy terms, exclusions, medical necessity requirements, and relevant insurance regulations. Experimental or investigational treatment may be excluded under particular policies.

Government employees and other eligible beneficiaries may claim reimbursement under the applicable service rules or medical schemes. A claim must be assessed according to the governing policy, relevant judicial precedents, and the circumstances of the treatment.

3. PRINCIPAL REGULATORY REQUIREMENTS

A. REGULATORY AUTHORISATION

The therapy must be administered under an applicable legal pathway, such as an authorised clinical trial or another legally permitted route. Experimental status does not itself establish that a treatment is lawful or eligible for reimbursement.

B. INFORMED CONSENT

Patients should receive clear information about investigational status, known risks, uncertainty of benefit, alternative treatments, and financial responsibility. Consent to experimental treatment does not waive statutory rights to compensation where those rights apply.

C. MEDICAL NECESSITY AND EVIDENCE

Reimbursement authorities should evaluate the diagnosis, clinical justification, available alternatives, evidence supporting the proposed therapy, and the applicable eligibility criteria.

D. SEPARATION OF FINANCIAL OBLIGATIONS

Reimbursement for treatment expenses must be distinguished from compensation for trial-related injury, payment for participation, and sponsor-funded trial medication. Each category has its own legal basis.

4. RELEVANT CASE LAWS

1. Swasthya Adhikar Manch v. Union of India (2014) 14 SCC 496 — DIRECT CLINICAL-TRIAL AUTHORITY

The Supreme Court examined safeguards governing clinical trials, including participant safety and regulatory oversight. The case supports strict protection of research participants but does not create a general right to reimbursement for experimental therapies obtained independently.

2. State of Punjab v. Mohinder Singh Chawla (1997) 2 SCC 83 — DIRECT MEDICAL-REIMBURSEMENT AUTHORITY

The Supreme Court recognised the State's obligation to provide medical facilities as an aspect of the right to life and considered reimbursement for medical treatment under the applicable service framework.

Relevance: It supports claims for eligible medical expenses where the governing legal framework imposes a reimbursement obligation. It does not guarantee payment for every investigational therapy.

3. State of Punjab v. Ram Lubhaya Bagga (1998) 4 SCC 117 — DIRECT HEALTHCARE-POLICY AUTHORITY

The Supreme Court considered the government's authority to formulate and revise medical reimbursement policies, recognising that healthcare policy must balance individual needs with available public resources.

Relevance: Experimental therapy claims must be evaluated under the applicable policy, while remaining subject to constitutional and administrative-law review.

4. Shiva Kant Jha v. Union of India (2018) 16 SCC 187 — DIRECT MEDICAL-REIMBURSEMENT AUTHORITY

The Supreme Court addressed medical reimbursement for treatment obtained at a non-government hospital and emphasised the importance of the applicable healthcare policy and the circumstances of the treatment.

Relevance: It may support eligible reimbursement claims where treatment circumstances and governing rules justify payment. It does not independently establish a right to reimbursement for unapproved experimental medicines.

5. Common Cause v. Union of India (2018) 5 SCC 1 — ANALOGOUS MEDICAL-AUTONOMY AUTHORITY

The Supreme Court considered end-of-life autonomy, dignity, and the legal framework governing advance directives and withdrawal of life-sustaining treatment.

Relevance: It highlights the importance of patient autonomy and informed decision-making when treatment choices involve serious illness and uncertainty. It does not directly determine experimental therapy reimbursement.

6. Indian Medical Association v. V.P. Shantha (1995) 6 SCC 651 — ANALOGOUS HEALTHCARE-ACCOUNTABILITY AUTHORITY

The Supreme Court examined the application of consumer-protection law to medical services.

Relevance: Depending on the facts and applicable legislation, disputes involving medical services, representations, or deficient treatment may raise questions of legal accountability. The judgment does not establish automatic reimbursement for experimental therapies.

5. PRACTICAL COMPLIANCE MEASURES

Verify the therapy's regulatory status before treatment.

Obtain written medical justification and informed consent.

Confirm the insurer's policy terms or the applicable government reimbursement scheme.

Determine whether the sponsor must provide treatment or compensation under clinical-trial rules.

Maintain prescriptions, invoices, treatment records, regulatory permissions, and claim correspondence.

Require reasoned decisions on reimbursement claims and provide an appropriate appeal mechanism.

Avoid representing an experimental therapy as an established, approved treatment when it is not.

6. CONCLUSION

Experimental therapy reimbursement requires a careful distinction between treatment costs, trial-related medical management, compensation for injury, and ordinary insurance or government reimbursement. Indian law provides specific protections for clinical-trial participants and recognises healthcare-related constitutional interests, but it does not guarantee reimbursement for every investigational treatment.

The governing principle is that reimbursement must rest on an applicable statutory obligation, insurance contract, public scheme, or other legally recognised entitlement. Transparent medical justification, informed consent, regulatory compliance, and reasoned decisions are essential to balancing patient welfare with scientific uncertainty and limited healthcare resources.